CC BY 4.0 · Arq Neuropsiquiatr 2024; 82(S 02): S53-S176
DOI: 10.1055/s-0045-1806982
ID: 561
Area: Neuromuscular diseases
Presentation method: Presentation Poster

A real-world analysis of an XLMTM patient cohort from the MTM and CNM international patient registry

Chiara Marini-Betolo
1   Newcastle University and Newcastle Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, The John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, United Kingdom.
,
Ana Buj Bello
2   Genethon, 91000, Evry, France
3   Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare Research Unit UMR_S951, 91000, Evry, France.
,
Faryn Solomon
4   Astellas Gene Therapies, San Francisco, California, United States.
,
Jess Page
1   Newcastle University and Newcastle Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, The John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, United Kingdom.
,
Tmirah Haselkorn
4   Astellas Gene Therapies, San Francisco, California, United States.
,
Ioanna Pangou
1   Newcastle University and Newcastle Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, The John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, United Kingdom.
,
Julie Coats
4   Astellas Gene Therapies, San Francisco, California, United States.
,
Joanne Bullivant
1   Newcastle University and Newcastle Hospitals NHS Foundation Trust, Translational and Clinical Research Institute, The John Walton Muscular Dystrophy Research Centre, Newcastle upon Tyne, United Kingdom.
,
James J. Dowlling
5   The Hospital for Sick Children; Toronto, Canada.
,
Kennedy Kirk
6   Universidade do Estado do Rio de Janeiro, Faculdade de Ciências Médicas, Rio de Janeiro RJ, Brazil.
› Institutsangaben
 

    *Correspondence: jader.baima@astellas.com.

    Abstract

    Background: X-linked myotubular myopathy (XLMTM) is a rare genetic neuromuscular disorder for which there is limited real-world data.

    Objective: To describe demographic and clinical characteristics of male patients with XLMTM in the Myotubular Myopathy (MTM) and Centronuclear Myopathy (CNM) Patient Registry.

    Methods: We performed a cross-sectional analysis of a genetically confirmed, living male patient cohort with XLMTM from the international MTM and CNM Patient Registry. As the data are patient-entered, some analyses had different denominators due to varying response rates for certain questions. Results were de-identified and reported at the aggregate level from patients’ most recent data entry. Analyses were not performed for response rates ≤2 patients. Data lock was on July 22nd, 2022.

    Results: A total of N=88 patients were included. Mean age was 11.7 years (range: 0 to 59 years). Mean age at genetic report was 4.1 years (range: 0 to 46 years) for n=73 responding patients. Fifty-four of 85 responding patients (63.5%) had received a muscle biopsy. The best motor milestone reported by patients (n=79) was 43.2% unable to sit or walk without support, 7.4% able to walk supported, 16.1% able to sit on their own, 21.0% able walk on their own, and 12.4% unknown. Of 88 patients, most (73.9%) reported requiring ventilation at birth; approximately 45.5% reported currently utilizing ventilation ≥16 hours/day, 25.0% utilized <16 hours/day, including while sleeping and awake, 9.1% utilized ventilation <16 hours/day, but only while sleeping, and 10.2% did not utilize ventilation. Of 82 responses, 58.5% reported feeding tube only, 30.5% reported no feeding tube, and 11% reported a gastric or nasal tube with some oral feeding. Of 81 responses, 55.6%, 4.9%, and 29.6% reported using a wheelchair all the time, some of the time, and never, respectively.

    Conclusion: The MTM-CNM Patient Registry provides a unique opportunity to examine real-world data in patients with XLMTM with evidence of varying severity. Data suggests that the disease burden of XLMTM is substantial, with most patients experiencing limited motor function and requiring respiratory support at birth and in daily life. Use of assistive devices and gastric or nasal tubes was common. Limitations include varying response rates, missing data, and the cross-sectional nature of this analysis. These data contribute to the understanding of XLMTM and highlight the need for improved treatments for these patients.


    #

    Publikationsverlauf

    Artikel online veröffentlicht:
    12. Mai 2025

    © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

    Thieme Revinter Publicações Ltda.
    Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil